Literature DB >> 33942355

Spotlight commentary: A role for real-world evidence to inform the clinical care of patients with diabetes mellitus.

Charles E Leonard1, James H Flory2, Robert Likić3, Olayinka O Ogunleye4, Li Wei5, Ian Wong5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33942355      PMCID： PMC9479484          DOI： 10.1111/bcp.14882

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   3.716


× No keyword cloud information.
  10 in total

1.  Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.

Authors:  Jong-Mi Seong; Jeong Yee; Hye Sun Gwak
Journal:  Br J Clin Pharmacol       Date:  2019-06-04       Impact factor: 4.335

2.  Real-world evidence in diabetes: relevance to clinical practice.

Authors:  Lawrence Blonde; Timothy Bailey; Jodi Strong; Philip Levin
Journal:  J Fam Pract       Date:  2019-04       Impact factor: 0.493

3.  Interest and challenges of pharmacoepidemiology for the study of drugs used in diabetes.

Authors:  Francesco Salvo; Jean-Luc Faillie
Journal:  Therapie       Date:  2018-10-28       Impact factor: 2.070

4.  Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease.

Authors:  Sherif S Farag; Mohammad Abu Zaid; Jennifer E Schwartz; Teresa C Thakrar; Ann J Blakley; Rafat Abonour; Michael J Robertson; Hal E Broxmeyer; Shuhong Zhang
Journal:  N Engl J Med       Date:  2021-01-07       Impact factor: 91.245

Review 5.  The present and future scope of real-world evidence research in diabetes: What questions can and cannot be answered and what might be possible in the future?

Authors:  Francesco Zaccardi; Melanie J Davies; Kamlesh Khunti
Journal:  Diabetes Obes Metab       Date:  2020-04       Impact factor: 6.577

Review 6.  Pharmacoepidemiology: Using randomised control trials and observational studies in clinical decision-making.

Authors:  Thomas M Caparrotta; James W Dear; Helen M Colhoun; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2019-07-24       Impact factor: 4.335

7.  Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study.

Authors:  Kristian B Filion; Antonios Douros; Laurent Azoulay; Hui Yin; Oriana H Yu; Samy Suissa
Journal:  Br J Clin Pharmacol       Date:  2019-07-31       Impact factor: 4.335

8.  Cost-effectiveness of long-acting insulin analogues vs intermediate/long-acting human insulin for type 1 diabetes: A population-based cohort followed over 10 years.

Authors:  Tsung-Ying Lee; Shihchen Kuo; Chen-Yi Yang; Huang-Tz Ou
Journal:  Br J Clin Pharmacol       Date:  2020-01-23       Impact factor: 4.335

9.  Association of insulin regimens with severe hypoglycaemia in patients with type 1 diabetes: A Danish case-control study.

Authors:  Morten Hasselstrøm Jensen; Ole Hejlesen; Peter Vestergaard
Journal:  Br J Clin Pharmacol       Date:  2020-03-06       Impact factor: 4.335

10.  Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals?

Authors:  Hans-Georg Eichler; Brigitte Bloechl-Daum; Karl Broich; Paul Alexander Kyrle; Jillian Oderkirk; Guido Rasi; Rui Santos Ivo; Ad Schuurman; Thomas Senderovitz; Luke Slawomirski; Martin Wenzl; Valerie Paris
Journal:  Clin Pharmacol Ther       Date:  2018-10-14       Impact factor: 6.875
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.